Wright Medical Group received a $2.4 million grant from the U.S. Department of Defense to fund a clinical study of OSTEOSET T bone graft substitute pellets in combat-related open fracture wounds, according to a company news release.
OSTEOSET T is a surgical grade calcium sulfate bone graft substituted impregnated with four percent tobramycin sulfate, which is designed to release at a predictable rate and act as a resorbable scaffold for new bone. The substance is available in pellet form and is equivalent to the OSTEOSET bone graft substitute, which does not contain tobramycin.
Pending FDA approval of OSTEOSET T, the company will conduct a clinical study with members of the U.S. military who have suffered combat-related open fractures. The OSTEOSET T is designed to lower reoperation and infection rates, according to the release.
Read the Wright Medical Group release on OSTEOSET T.
Read other coverage on Wright Medical Group:
- Wright Medical Group Launches Valor Ankle Fusion Nail System
- Wright Receives FDA Approval for Conserve Plus Hip Resurfacing System
- Wright Medical Group Reports Net Sales of $127.7M
OSTEOSET T is a surgical grade calcium sulfate bone graft substituted impregnated with four percent tobramycin sulfate, which is designed to release at a predictable rate and act as a resorbable scaffold for new bone. The substance is available in pellet form and is equivalent to the OSTEOSET bone graft substitute, which does not contain tobramycin.
Pending FDA approval of OSTEOSET T, the company will conduct a clinical study with members of the U.S. military who have suffered combat-related open fractures. The OSTEOSET T is designed to lower reoperation and infection rates, according to the release.
Read the Wright Medical Group release on OSTEOSET T.
Read other coverage on Wright Medical Group:
- Wright Medical Group Launches Valor Ankle Fusion Nail System
- Wright Receives FDA Approval for Conserve Plus Hip Resurfacing System
- Wright Medical Group Reports Net Sales of $127.7M